The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels

Blood Rev. 2016 Nov;30(6):421-429. doi: 10.1016/j.blre.2016.05.002. Epub 2016 May 19.

Abstract

Increased plasma plasminogen activator inhibitor-1 (PAI-1) level is considered a mechanistic pathway through which obesity contributes to increased cardiovascular disease risk. Abdominal adipose tissue specifically, is a major PAI-1 source with visceral adipose tissue (VAT), an ectopic fat depot, generally considered to produce more PAI-1 than subcutaneous adipose tissue. However, this does not necessarily lead to increased plasma PAI-1 levels. This review provides an overview of studies investigating the association between body fat distribution and plasma PAI-1 levels. It discusses factors that influence this relationship and also considers the contribution of other tissue to plasma PAI-1 levels, placing the relative contribution of adipose tissue into perspective. In conclusion, the relationship between VAT and plasma PAI-1 levels is not fixed but can be modulated by a number of factors such as the size of the subcutaneous adipose tissue depot, ethnicity, possibly genetics and other obesity-related metabolic abnormalities.

Keywords: Body fat distribution; Plasminogen activator inhibitor-1; Subcutaneous adipose tissue; Visceral adipose tissue.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / metabolism*
  • Adipose Tissue / pathology
  • Age Factors
  • Animals
  • Biomarkers
  • Gene Expression
  • Humans
  • Obesity / genetics
  • Obesity / metabolism
  • Plasminogen Activator Inhibitor 1 / genetics
  • Plasminogen Activator Inhibitor 1 / metabolism*
  • Polymorphism, Genetic
  • Sex Factors

Substances

  • Biomarkers
  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human